It has been found that antimuscarinic drugs, viewed as the "gold standard" in overactive bladder syndrome (OAB) treatment, have an unsatisfactory tolerance profile and limited clinical effectiveness. This fact has given a clear impetus to search for new options in OAB pharmacotherapy. The conducted pre-clinical trials have led to the development of new solutions for the treatment of OAB, which stand a good chance of being applied in clinical practice. The said compounds are characterised by higher receptor and organ specificity than currently used medications.
Ginekologia polska. 2017 Jan [Epub]
Andrzej Wróbel, Tomasz Kluz, Grzegorz Surkont, Edyta Wlaźlak, Paweł Miotła, Katarzyna Skorupska, Tomasz Rechberger
Second Department of Gynecology, Medical University of Lublin,, Jaczewskiego 8, PL 20-090 Lublin, Poland, 20-090, Lublin, Poland. .